Open AccessAzacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia
Author(s) -
Amany R. Keruakous,
Jennifer HolterChakrabarty,
Sarah Schmidt,
Mohamad Khawandanah,
George B. Selby,
Carrie Yuen
Publication year - 2021
Publication title -
hematology/oncology and stem cell therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 22
eISSN - 2589-0646
pISSN - 1658-3876
DOI - 10.1016/j.hemonc.2021.03.001
Subject(s) - myeloid leukemia , azacitidine , medicine , transplantation , stem cell , oncology , leukemia , immunology , cancer research , biology , gene , biochemistry , genetics , gene expression , dna methylation
Allogeneic hematopoietic stem cell transplant (HSCT) is the potential curative modality for poor-risk acute myeloid leukemia (AML), relapse remains the main reason for transplant failure. Early-phase studies showed azacitidine is safe for post-transplant maintenance therapy in AML.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom